Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck: Second “Not Approvable” Letter In Two Days – This Time, Cordaptive

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA nixes name, too, for anti-cholesterol niacin/laropiprant combo.
Advertisement

Related Content

FDA Seeks Outcomes Data For Merck’s MK-0524A
Prasugrel: To Be (Approved) Or Not To Be
Prasugrel: To Be (Approved) Or Not To Be
FDA Seeks Outcomes Data For Merck’s MK-0524A
The Woodcock Effect: Is The New CDER Director Approving More Drugs?
Merck Cuts U.S. Sales Force By 1,200
Merck-Schering Claritin/Singulair Combo “Not Approvable” At FDA
Merck-Schering Claritin/Singulair Combo “Not Approvable” At FDA
Abbott Won’t Shrink From Competitor Merck’s Cordaptive
Merck's Cordaptive: Just Another Cholesterol Combo, or More?

Topics

Advertisement
UsernamePublicRestriction

Register

PS067669

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel